CN115461368A - 抗人白细胞介素-4受体α抗体及其制备方法和应用 - Google Patents

抗人白细胞介素-4受体α抗体及其制备方法和应用 Download PDF

Info

Publication number
CN115461368A
CN115461368A CN202180028819.7A CN202180028819A CN115461368A CN 115461368 A CN115461368 A CN 115461368A CN 202180028819 A CN202180028819 A CN 202180028819A CN 115461368 A CN115461368 A CN 115461368A
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028819.7A
Other languages
English (en)
Inventor
张成海
郭锦林
袁玉菁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Mabgeek Biotechnology Co ltd
Original Assignee
Shanghai Mabgeek Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Mabgeek Biotechnology Co ltd filed Critical Shanghai Mabgeek Biotechnology Co ltd
Publication of CN115461368A publication Critical patent/CN115461368A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

提供了能够结合人白细胞介素4受体α(hIL‑4Rα)的抗体以及其制备方法和应用。该抗hIL‑4Rα抗体能够与hIL‑4Rα特异性结合，具有良好的抑制IL‑4和IL‑13诱导的细胞系增殖等效果，可应用于治疗IL‑4Rα相关疾病，例如免疫介导的炎症性疾病。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202180028819.7A 2020-04-17 2021-04-13 抗人白细胞介素-4受体α抗体及其制备方法和应用 Pending CN115461368A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020103092388 2020-04-17
CN202010309238.8A CN113527485A (zh) 2020-04-17 2020-04-17 抗人白细胞介素-4受体α抗体及其制备方法和应用
PCT/CN2021/086806 WO2021208881A1 (zh) 2020-04-17 2021-04-13 抗人白细胞介素-4受体α抗体及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN115461368A true CN115461368A (zh) 2022-12-09

Family

ID=78084043

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010309238.8A Pending CN113527485A (zh) 2020-04-17 2020-04-17 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN202180028819.7A Pending CN115461368A (zh) 2020-04-17 2021-04-13 抗人白细胞介素-4受体α抗体及其制备方法和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010309238.8A Pending CN113527485A (zh) 2020-04-17 2020-04-17 抗人白细胞介素-4受体α抗体及其制备方法和应用

Country Status (13)

Country Link
US (2) US11939387B2 (zh)
EP (1) EP4137517A4 (zh)
JP (1) JP7454882B2 (zh)
KR (1) KR20230004576A (zh)
CN (2) CN113527485A (zh)
AU (1) AU2021255445A1 (zh)
BR (1) BR112022021030A2 (zh)
CA (1) CA3175786A1 (zh)
CL (1) CL2022002863A1 (zh)
IL (1) IL297312A (zh)
MX (1) MX2022013034A (zh)
WO (1) WO2021208881A1 (zh)
ZA (1) ZA202211889B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210403580A1 (en) * 2018-11-09 2021-12-30 Ajou University Industry-Academic Cooperation Foundation Human antibody having high affinity to human il-4 receptor alpha, and use thereof
WO2023208104A1 (zh) * 2022-04-29 2023-11-02 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途
CN115353566B (zh) * 2022-09-14 2023-05-09 江苏睿源生物技术有限公司 用于检测白细胞介素1-β的抗体组合及其应用
CN116178552A (zh) * 2022-12-30 2023-05-30 合肥天港免疫药物有限公司 抗cd94的抗体及其应用
CN118105485B (zh) * 2024-04-26 2024-09-03 湖南麦济生物技术有限公司 一种稳定的抗人IL-4Rα单克隆抗体制剂

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050058645A1 (en) * 2002-03-22 2005-03-17 Amrad Operations Pty. Ltd. Monoclonal antibody against Interleukin-13 receptor alpha 1 (IL-13Ralpha1)
US20090202568A1 (en) * 2007-12-21 2009-08-13 Astrazeneca Ab Binding members for interleukin-4 receptor alpha (IL-4Ra)-173
CN101512008A (zh) * 2006-09-08 2009-08-19 艾博特公司 白介素-13结合蛋白
CN102046658A (zh) * 2007-12-21 2011-05-04 米迪缪尼有限公司 白介素-4受体α(IL-4Rα)-173的结合成员
US20130072420A1 (en) * 2010-05-21 2013-03-21 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
US20140056920A1 (en) * 2012-08-21 2014-02-27 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing asthma by administering an il-4r antagonist
US8980273B1 (en) * 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CN106336459A (zh) * 2015-07-13 2017-01-18 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
CN108409860A (zh) * 2017-02-10 2018-08-17 上海麦济生物技术有限公司 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
CN109311974A (zh) * 2016-06-12 2019-02-05 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
CN109776677A (zh) * 2017-11-15 2019-05-21 上海开拓者生物医药有限公司 一种人源化抗il-13抗体及其制备方法和应用
US20190169299A1 (en) * 2017-10-30 2019-06-06 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US20190177408A1 (en) * 2016-06-08 2019-06-13 Suzhou Connect Biopharmaceuticals, Ltd Antibody for binding to interleukin 4 receptor
CN110167963A (zh) * 2016-12-01 2019-08-23 瑞泽恩制药公司 治疗发炎病况的方法
CN110746507A (zh) * 2018-12-25 2020-02-04 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
MY124565A (en) 1996-07-19 2006-06-30 Bayer Corp High-affinity interleukin-4-muteins
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
GEP20104991B (en) * 2003-11-07 2010-05-25 Immunex Corp Antibodies that bind interleukin-4 receptor
DK2769992T3 (da) 2006-10-02 2021-03-22 Regeneron Pharma Humane antistoffer med høj affinitet for human IL-4-receptor
KR20150021088A (ko) 2012-06-05 2015-02-27 디 오스트레일리언 내셔널 유니버시티 인터루킨-4 길항제를 이용한 백신접종
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
NO2785538T3 (zh) * 2014-05-07 2018-08-04
BR112017003419A2 (pt) * 2014-09-03 2017-11-28 Medimmune Ltd formulação de anticorpo anti-il-4r-alfa estável
CA3005696A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
CN110105451B (zh) * 2018-02-01 2020-12-18 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
CN108373505B (zh) 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
CN110540590B (zh) * 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用
CN110872349A (zh) 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
BR112021012647A2 (pt) 2018-12-27 2021-09-14 Akeso Biopharma, Inc Anticorpo, polipeptídeo isolado, polinucleotídeo isolado, vetor, célula hospedeira, métodos para preparar o anticorpo e para a prevenção e/ou tratamento e/ou tratamento adjuvante e/ou diagnóstico de uma doença, conjugado de anticorpo, anticorpo multiespecífico, proteína de fusão, composição farmacêutica, kit, usos do anticorpo, método in vivo ou in vitro, célula de hibridoma e anticorpo monoclonal
CN116583539A (zh) 2020-12-22 2023-08-11 江苏恒瑞医药股份有限公司 抗il-4r抗体或其抗原结合片段的复合物及医药用途

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050058645A1 (en) * 2002-03-22 2005-03-17 Amrad Operations Pty. Ltd. Monoclonal antibody against Interleukin-13 receptor alpha 1 (IL-13Ralpha1)
CN101512008A (zh) * 2006-09-08 2009-08-19 艾博特公司 白介素-13结合蛋白
US20090202568A1 (en) * 2007-12-21 2009-08-13 Astrazeneca Ab Binding members for interleukin-4 receptor alpha (IL-4Ra)-173
CN102046658A (zh) * 2007-12-21 2011-05-04 米迪缪尼有限公司 白介素-4受体α(IL-4Rα)-173的结合成员
US20130072420A1 (en) * 2010-05-21 2013-03-21 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
US20140056920A1 (en) * 2012-08-21 2014-02-27 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing asthma by administering an il-4r antagonist
US8980273B1 (en) * 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CN106336459A (zh) * 2015-07-13 2017-01-18 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
US20190177408A1 (en) * 2016-06-08 2019-06-13 Suzhou Connect Biopharmaceuticals, Ltd Antibody for binding to interleukin 4 receptor
CN109311974A (zh) * 2016-06-12 2019-02-05 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
CN110167963A (zh) * 2016-12-01 2019-08-23 瑞泽恩制药公司 治疗发炎病况的方法
CN108409860A (zh) * 2017-02-10 2018-08-17 上海麦济生物技术有限公司 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
US20190169299A1 (en) * 2017-10-30 2019-06-06 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
CN109776677A (zh) * 2017-11-15 2019-05-21 上海开拓者生物医药有限公司 一种人源化抗il-13抗体及其制备方法和应用
CN110746507A (zh) * 2018-12-25 2020-02-04 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
UL-HAQ, ZAHEER等: "Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box", 《CYTOKINE & GROWTH FACTOR REVIEWS》, vol. 32, 28 December 2016 (2016-12-28), pages 3 - 15, XP029821543, DOI: 10.1016/j.cytogfr.2016.04.002 *
成家军等: "联合应用IL-4突变体及抗IL-25抗体对哮喘小鼠炎性细胞及细胞因子水平的影响", 《临床肺科杂志》, vol. 25, no. 03, 9 March 2020 (2020-03-09), pages 377 - 380 *

Also Published As

Publication number Publication date
AU2021255445A1 (en) 2022-12-08
IL297312A (en) 2022-12-01
EP4137517A1 (en) 2023-02-22
ZA202211889B (en) 2023-07-26
JP7454882B2 (ja) 2024-03-25
KR20230004576A (ko) 2023-01-06
BR112022021030A2 (pt) 2022-12-06
CA3175786A1 (en) 2021-10-21
CN113527485A (zh) 2021-10-22
US20230203172A1 (en) 2023-06-29
US20240190979A1 (en) 2024-06-13
WO2021208881A1 (zh) 2021-10-21
US11939387B2 (en) 2024-03-26
CL2022002863A1 (es) 2023-04-14
JP2023515260A (ja) 2023-04-12
MX2022013034A (es) 2022-11-09
EP4137517A4 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
CN108409860B (zh) 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
WO2017215524A1 (zh) 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
CN115461368A (zh) 抗人白细胞介素-4受体α抗体及其制备方法和应用
CA3148491C (en) Humanized anti-il17a antibody and use thereof
EP4289861A1 (en) Antibodies against human tslp and use thereof
CN111615519B (zh) 结合人il-5的单克隆抗体、其制备方法和用途
CN112041347B (zh) 结合人il-4r的抗体、其制备方法和用途
CN112480254B (zh) 抗人白细胞介素-33受体的抗体及其制备方法和应用
EP4242229A1 (en) Antibody against human thymic stromal lymphopoietin, preparation method therefor and application thereof
KR20210102946A (ko) 항il-17a 항체 및 이의 응용
WO2022218061A1 (zh) 抗人masp-2抗体及其制备方法和应用
CN112480252B (zh) 抗白细胞介素-33抗体及其制备方法和应用
US20210332123A1 (en) Anti-il-25 antibodies and use thereof
RU2807060C1 (ru) Антитело к альфа-рецептору интерлейкина-4 человека, способ его получения и его применение
CN114437215B (zh) 抗人cd38抗体及其制备方法和用途
WO2021218574A1 (zh) 结合人ngf的抗体、其制备方法和用途
CN112513078A (zh) 抗il-17a抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078092

Country of ref document: HK